Health

AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival


FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid

(Reuters) – AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study.

The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone.

Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population.

Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.